Infectious Disease · Clinical trials
Malaria Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About malaria — and why its trials are hard
Malaria is a mosquito-borne parasitic disease caused by Plasmodium species, with P. falciparum driving most severe illness and deaths and P. vivax notable for dormant liver-stage hypnozoites that cause relapse. Treatment of uncomplicated falciparum malaria rests on artemisinin-based combination therapies (ACTs), which pair a fast-acting artemisinin derivative with a longer-acting partner drug to clear parasites and limit resistance; artemether-lumefantrine (Coartem) is a widely used example. Atovaquone-proguanil (Malarone) serves for treatment and prophylaxis. For P. vivax, radical cure of hypnozoites historically required a two-week primaquine course; single-dose tafenoquine (Krintafel) now offers a convenient alternative, though both require G6PD testing. A major recent advance is vaccination: RTS,S/AS01 (Mosquirix) and R21/Matrix-M are recommended by the WHO for children in endemic regions, with efficacy measured as protection against clinical malaria. Emerging artemisinin partial resistance in Africa and Southeast Asia threatens ACTs and drives development of new drugs and combinations.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Artemether-lumefantrine (Coartem) | 2009 (US FDA) | Uncomplicated P. falciparum malaria | Pooled registrational ACT studies | 28-day PCR-corrected parasitological cure rate | Cure rates typically >95% in efficacy trials |
| Atovaquone-proguanil (Malarone) | 2000 (US FDA) | Treatment and prophylaxis of uncomplicated malaria | Registrational treatment/prophylaxis trials | Parasitological cure / protective efficacy | High cure and prophylactic efficacy in registrational studies |
| Tafenoquine (Krintafel) | 2018 (US FDA) | Radical cure (anti-relapse) of P. vivax malaria, single dose (with chloroquine); G6PD testing required | GATHER / DETECTIVE (phase 3) | Recurrence-free efficacy at 6 months | Significantly higher relapse-free rate vs placebo; comparable to 14-day primaquine |
| R21/Matrix-M vaccine (R21/Matrix-M) | WHO recommended 2023 (not FDA-approved) | Prevention of clinical malaria in children in endemic areas | Phase 3 multicentre trial (Lancet 2024) | Vaccine efficacy against clinical malaria over 12 months | ~75% efficacy at seasonal sites and ~68% at standard sites over 12 months |
| RTS,S/AS01 vaccine (Mosquirix) | WHO recommended 2021 (not FDA-approved) | Prevention of P. falciparum malaria in young children | Phase 3 (Lancet 2015) | Efficacy against clinical malaria | ~36% efficacy against clinical malaria over ~4 years with 4 doses in young children |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in malaria development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Halofantrine — Post-marketing safety experience | Effective antimalarial but restricted due to cardiotoxicity | QT prolongation and risk of fatal arrhythmias limited use in favor of safer ACTs |
Choosing the right endpoint
Primary endpoints that matter in malaria trials
- PCR-corrected parasitological cure — 28- or 42-day cure distinguishing true recrudescence from new infection; primary drug-efficacy measure
- Vaccine efficacy against clinical malaria — Relative reduction in incident symptomatic malaria in vaccinees vs controls; primary vaccine endpoint
- Radical cure / relapse-free rate — For P. vivax, freedom from recurrence over 6 months reflects hypnozoite clearance
- Parasite clearance time — Rate of parasite reduction after artemisinin; delayed clearance flags partial resistance
How iNGENū runs malaria trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Malaria clinical trials — FAQs
What are ACTs?
Why is G6PD testing needed before tafenoquine or primaquine?
How effective are malaria vaccines?
Ready to discuss your malaria trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal